Astra Enters Into $2 Billion-Plus Pact With UK Biotech Quell
- Astra, Quell to develop cell therapies for autoimmune diseases
- Deal is first major partnership for UK biotech Quell
This article is for subscribers only.
AstraZeneca Plc entered a collaboration with UK biotech Quell Therapeutics potentially worth more than $2 billion to develop cell therapies against major autoimmune diseases.
The companies will develop technologies to tackle type 1 diabetes and inflammatory bowel disease, Astra said Friday.